News

Recently published in Supportive Care in Cancer, a team from Markey Cancer Center utilized Kentucky Cancer Registry data to identify if there was a correlation between individuals suffering from financial toxicity and comprehension of health insurance.

The UK Markey Cancer Center has officially launched a unique new clinical trial to test whether Artemisia annua extract can prevent ovarian cancer recurrence.

The Summer HealthCare Experience (SHE) in Oncology program, is aimed at empowering high school girls throughout Kentucky to learn more about the field of cancer medicine and research. The inaugural program will be held July 12-23 and will be virtual due to the ongoing pandemic.

Kentucky is the only state currently growing substantial quantities of Artemisia annua, meaning the Commonwealth could become a new epicenter for growing the plant worldwide. The plant’s growth could potentially give Kentucky’s farmers a new cash crop to supplement income. 

Faculty and students from the UK College of Nursing and UK College of Education Department of Kinesiology and Health Promotion were among key leaders in cancer prevention, journalism, education and government who contributed to an educational session during the 2021 National Cancer Prevention Workshop.

The curriculum includes information on cancer data and risk factors in the region, follows national and state science and health education standards, and is tailored to cultural aspects of Appalachian Kentucky.

The University of Kentucky Markey Cancer Center is teaming up with the National Comprehensive Cancer Network® (NCCN®), the American Cancer Society (ACS) and other leading cancer organizations across the country to endorse the resumption of cancer screening and treatment during the ongoing COVID-19 pandemic.

A new study by UK Markey Cancer Center researchers shows that DACH1 mutations are prevalent in Kentucky patients with endometrial cancer, suggesting that DACH1 may be a candidate biomarker for future trials with immunotherapy.

A major initiative of Williams and the Markey Community Impact Office will be the organization and expansion of Markey’s research and outreach portfolio that is focused on reducing cancer and other health disparities based on race/ethnicity, socioeconomic status, etc.

Building on these findings, Plattner and Markey oncologists are now collaborating with the pharmaceutical company Novartis to develop a Phase I clinical trial to test the safety and effectiveness of using nilotinib in relapsed melanoma patients.